OS Therapies Statistics
Total Valuation
OS Therapies has a market cap or net worth of $42.24 million. The enterprise value is $36.71 million.
| Market Cap | 42.24M |
| Enterprise Value | 36.71M |
Important Dates
The next estimated earnings date is Monday, May 19, 2025, before market open.
| Earnings Date | May 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
OS Therapies has 21.66 million shares outstanding. The number of shares has increased by 127.97% in one year.
| Current Share Class | 21.66M |
| Shares Outstanding | 21.66M |
| Shares Change (YoY) | +127.97% |
| Shares Change (QoQ) | +36.87% |
| Owned by Insiders (%) | 30.10% |
| Owned by Institutions (%) | 1.70% |
| Float | 12.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 2.88 |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 52.06 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.20
| Current Ratio | 1.20 |
| Quick Ratio | 1.20 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.32 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -134.41% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -747.55% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.18M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 1.63 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 55.28 |
| Average Volume (20 Days) | 339,114 |
Short Selling Information
The latest short interest is 8,931, so 0.04% of the outstanding shares have been sold short.
| Short Interest | 8,931 |
| Short Previous Month | n/a |
| Short % of Shares Out | 0.04% |
| Short % of Float | 0.07% |
| Short Ratio (days to cover) | 0.01 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.81M |
| Pretax Income | n/a |
| Net Income | -10.89M |
| EBITDA | -6.81M |
| EBIT | -6.81M |
| Earnings Per Share (EPS) | -$0.88 |
Balance Sheet
The company has $5.53 million in cash and n/a in debt, giving a net cash position of $5.53 million or $0.26 per share.
| Cash & Cash Equivalents | 5.53M |
| Total Debt | n/a |
| Net Cash | 5.53M |
| Net Cash Per Share | $0.26 |
| Equity (Book Value) | 811,487 |
| Book Value Per Share | -0.25 |
| Working Capital | 906,217 |
Cash Flow
| Operating Cash Flow | -7.28M |
| Capital Expenditures | n/a |
| Free Cash Flow | -7.28M |
| FCF Per Share | -$0.34 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OS Therapies does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -127.97% |
| Shareholder Yield | n/a |
| Earnings Yield | -25.77% |
| FCF Yield | -17.24% |
Analyst Forecast
The average price target for OS Therapies is $18.00, which is 823.08% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.00 |
| Price Target Difference | 823.08% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |